Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Evotec, Renovis deal

EVT will acquire RNVS for $4.75 per share, or about $151.8 million in stock. The price is a 43% premium to RNVS's close of $3.32 on Sept.

Read the full 275 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE